Cleveland BioLabs, Inc.  

(Public, NASDAQ:CBLI)   Watch this stock  
Find more results for CBLI
0.600
-0.030 (-4.75%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.58 - 0.66
52 week 0.54 - 2.06
Open 0.63
Vol / Avg. 223,057.00/703,340.00
Mkt cap 30.56M
P/E     -
Div/yield     -
EPS -0.38
Shares 50.92M
Beta 1.94
Inst. own 19%
Feb 11, 2014
CLEVELAND BIOLABS INC at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -21.82% -237.15%
Operating margin -77.39% -271.88%
EBITD margin - -266.32%
Return on average assets -19.71% -86.20%
Return on average equity - -
Employees 85 -
CDP Score - -

Address

73 High Street
BUFFALO, NY 14203
United States - Map
+1-716-8496810 (Phone)
+1-716-8496820 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company with a focus on oncology drug development. The Company�s lead drug candidate CBLB502 is developed for dual indications under the United States Food & Drug Administration's (FDA's) Animal Efficacy Rule, commonly referred to as the Animal Rule, as a radiation countermeasure, and under the FDA's traditional drug approval pathway as an anti-cancer agent and an oncology supportive care therapy. As of December 31, 2011, the Company had nine product candidates in its pipeline that are developed directly by the Company and its majority owned subsidiaries. The products include CBLB502, CBLB502, CBLB502, CBLB612, CBLC102, CBLC137, Revercom, Mobilan, Arkil, Antimycon, and Xenomycins. As of December 31, 2011, the Company had an approximately 75.8% ownership interest in Incuron, LLC (Incuron).As of December 31, 2011, the Company had an ownership stake of approximately 54.6% in Panacela Labs, Inc. (Panacela).

Officers and directors

David C. Hohn M.D. Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Yakov N. Kogan Ph.D Chief Executive Officer, Director
Age: 40
Bio & Compensation  - Reuters
C. Neil Lyons CPA Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Andrei V. Gudkov Ph.D. Chief Scientific Officer, Director
Age: 56
Bio & Compensation  - Reuters
James J. Antal CPA Independent Director
Age: 62
Bio & Compensation  - Reuters
Julia R. Brown Independent Director
Age: 66
Bio & Compensation  - Reuters
Paul E. DiCorleto Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Anthony J. Principi J.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Randy S. Saluck J.D. Independent Director
Age: 47
Bio & Compensation  - Reuters